Citations

Clear

313 citation(s) found for "Alvarez, P".

Safety and efficacy of immune checkpoint inhibitors (ICI) in advanced penile squamous cell carcinoma (PeCa): An international study from the Global Society of Rare Genitourinary Tumors (GSRGT).
Zarif, Talal El , Nassar, Amin, Jiang, Lijuan , Pond, Gregory R. , Zhuang, Tony , Velev, Maud , Álvarez, Pablo, McKay, Rana R. , El‐Am, Edward , Hui, Gavin , Milowsky, Matthew I. , Matthews, Harrison, Sonpavde, Guru , Pond, Gregory Russell , Nassar, Amin H. , Hahn, Andrew W. , Buti, Sebastiano , Vincenzi, Bruno , Lee, Jae‐Lyun , Mouhieddine, Tarek H. , Barata, Pedro C. , Apolo, Andrea B

Mayo Clinic

Journal of Clinical Oncology | March 14, 2023 | Volume: 41 | Issue: 6_suppl | Pages: 5-5

10.1200/jco.2023.41.6_suppl.5 Get It

5 Background: Management options for patients (pts) with advanced (locally advanced or metastatic) PeCa are limited. The GSRGT assembled an international cohort of pts with advanced PeCa treated with ICI to evaluate toxicity and clinical outcomes. Methods: We retrospectively collected data on pts with advanced PeCa receiving ≥1 cycle of ICI between 2015-2022 at 18 medical centers in the US, Europe, and Asia. Immune-related adverse events (irAE) were graded per the Common Terminology Criteria for Adverse Events v5.0. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method. Objective response rate (ORR) was determined by the clinical investigator per RECIST 1.1 criteria, whenever feasible. Results: Among 72 pts with advanced PeCa treated with ICI, 24 (33%) were Hispanic and 7 (10%) were Black. 60 (83%) pts had metastases while the remainder had locally advanced disease. The median age was 64 (inter-quartile range (IQR): 54,70) years and 48 (67%) had ECOG performance status ≥1. Most pts (n=60, 83%) were treated in the ≥2nd line setting and received pembrolizumab (n=23), nivolumab (n=15), cemiplimab (n=15), nivolumab and ipilimumab (n=7), or other anti-PD1/L1-based therapies (n=12). Among 37 pts with available data on HPV status, 24 (65%) were HPV+. 3 (4%) pts were HIV+. irAE of any grade occurred in 18 (25%) pts, 7 (10%) were grade ≥3, 7 (10%) required steroids, 6 (9%) required hospitalization, and 8 (11%) led to treatment discontinuation. The median OS and 24-month OS and median PFS and 24-month PFS were 9.4 (95%CI: 6.8, 12.8) months and 19.3% (95%CI: 9.2, 32.1) and 2.8 (95%CI: 2.1, 3.9) months and 11.2 % (95%CI: 4.9, 20.2), respectively. Among 66 pts evaluable for response, ORR was 7/66 (11%) (2 with complete response, 5 with partial response), and 16 (24%) pts had stable disease for a disease control rate of 35%. The median duration of response was 7.9 (IQR: 3, not reached) months. Conclusions: In the largest retrospective cohort of ICI-treated advanced PeCa, ICI showed no new safety signals, however, overall anti-tumor activity was limited. Future translational studies are needed to identify pts that are more likely to derive clinical benefit from ICI.
Mechanical Thrombectomy Global Access For Stroke (MT-GLASS): A Mission Thrombectomy (MT-2020 Plus) Study
Asif, Kaiz , Otite, Fadar Oliver , Desai, Shashvat M. , Herial, Nabeel , Inoa, Violiza , Al‐Mufti, Fawaz , Dmytriw, Adam A. , Castonguay, Alicia C. , Khandelwal, Priyank , Potter‐Vig, Jennifer , Szeder, Viktor , Kulman, Tanzila, Masoud, Hesham , Tóth, Gábor , Limaye, Kaustubh , Aroor, Sushanth , Brinjikji, Waleed , Rai, Ansaar , Gebreyohanns, Mehari , Leung, Thomas , Mansour, Malek , Huded, Vikram , Zaidat, Osama O. , Sylaja, PN , Yavagal, Dileep R. , Cirio, Juan , Lylyk, Pedro , Ferrario, Ángel, Plaghos, Luis Lemme, Ibrahim, Wael Hamed, Alnidawi, Firas , Islam, Sirajee Shafiqul, Shahidullah, Mohammad, Saavedra, Víctor Villarroel, Alverne, Francisco Josà Mont’, Magalhães, Pedro , Sirakov, Stanimir , Kalpachki, Rosen, Alioski, Nurfet, Lamou, Eric Gueumekane Bila , Rowe, Daidre, Gayle, Francene , Souza, Romnesh de, Ramos, Cristina , GarcÃa, Amaury, Ali, Amza , Sandy, Sherry , Guzman, Tony Fabian Alvarez, Villarraga, Alejandro, Estrada, Carolina, Pabón, B , Adebayo, Philip , ABDO, GERMAN, S, Nelson Maldonado, Khinikadze, Mirza, Tsiskaridze, Alexander , Syrmos, Νikolaos , Mitsias, Panayiotis , Das, Biplab , Gupta, Vipul , Karapurkar, Anil, Stivastava, M.V.Padma, Alurkar, Anand, Sharma, Arvind , Lahoti, Satish, Kuruttukulam, Gigy , Sari, Ita Muharram , Khassaf, Mustafa Saleem, Nassir, Temeem Majid, Yamagami, Hiroshi , Dababneh, Haitham, Aladham, Farid A., Berdikhojayev, Mynzhylky , Medukhanova, Sabina , Kikano, Raghid, Alaraj, Ali , Ahdab, Rechdi , Zaidi, Wan Asyraf Wan , Kadir, Khairul Azmi Abd, Gongora, Fernando, Jambaldorj, Ariunaa , XXX, Ganbaatar, Shwe, Zarni Myint, Thit, Win Min , RAYO, ERWIN E., Makanjuola, Akintomiwa , Rashid, Umair, Mernes, Ricardo, Paniagua, Osvaldo, GALLO, MARLA, Moquillaza, Manuel, Collantes, Maria Epifania , Mariano, Manuel, Kobayashi, Adam , Rodríguez‐Mercado, Rafael, Guardia, Rodolfo Alcedo, Imam, Yahia , Ahmed, Ayman Z., Al-Jehani, Hosam , Lee, Wickly, Klepanec, Andrej , Brey, Naeem , Rossouw, Anastasia, Silva, Prasad De, Gunasekera, Harsha, Ranawaka, Udaya K. , Osman, Haytham , El-Sadig, Sarah , Suwanwela, Nijasri C., Akarathanawat, Wasan, Tantivatana, Jarturon , Hammami, Nadia, Giray, Semih , Lebedynets, Dmytro , Konotopchik, Stanislav, John, Seby , Hussain, Syed , Novakovic-White, Robin, Perue, Gillian L Gordon, Then, Ryna , Berrutti, Claudio, Crosa, Roberto , Nguyen, Huy Thang, Le, Huynh Vu, vu, Tran thanh, Asif, Kaiz S , Otite, Fadar O , Jadhav, Ashutosh P , Dmytriw, Adam A , Castonguay, Alicia , Khandelwal, Priyank , Szeder, Viktor , Urrutia, Victor C , Masoud, Hesham , Toth, Gabor , Limaye, Kaustubh , Brinjikji, Waleed , Rai, Ansaar , Pandian, Jeyaraj , Leung, Thomas , Mansour, Ossama , Demchuk, Andrew M , Martins, Sheila , Zaidat, Osama O , Huo, Xiaochuan , Campbell, Bruce , Miao, Zhongrong , Saver, Jeffrey , Ortega-Gutierrez, Santiago , Yavagal, Dileep R , Crosa, Roberto , Alaraj, Ali , Al-Mufti, Fawaz , Jadhav, Ashutosh P. , Urrutia, Victor , Pandian, Jeyaraj , Demchuk, Andrew M. , Saver, Jeffrey L. , Arroyo, José, Yan, Bernard , Chandra, Ronil Vikesh , Shahidullah, Mohammad, Alverne, F Mont, Silva, Gisele Sampaio , Shankar, Jai , Stotts, Grant , Ramos, Cristina, Lavados, Pablo M. , Rivera, Rodrigo , Krajina, Antonı́n , Tomek, Aleš , Hassan, Farouk , Khedr, Eman M. , Nadareishvili, Zurab , Roy, Jayanta , Gupta, Vivek , Khurana, Dheeraj , Kumar, Rahul Kewal , Sani, Achmad Firdaus , Sakai, Nobuyuki , Aladham, Farid, Kikano, Raghid , Araúz, Antonio , Góngora‐Rivera, Fernando , Shwe, Zarni Myint, Ranta, Annemarei , Wu, Teddy Y , Owolabi, Mayowa , Ahmad, Saima , Wasay, Mohammad , Alhazzani, Adel Ali , Zeleňák, Kamil , Krastev, Georgi , Frol, Senta , Hammami, Nadia, Sassi, Samia Ben , Özdemi̇r, Atilla Özcan , Конотопчик, С. В., Perue, Gillian Gordon

Mayo Clinic

Circulation | March 8, 2023 | Volume: 147 | Issue: 16 | Pages: 1208-1220

10.1161/circulationaha.122.063366 | PMID 36883458 Get It

Background: Despite the well-established potent benefit of mechanical thrombectomy (MT) for large vessel occlusion (LVO) stroke, access to MT has not been studied globally. We conducted a worldwide survey of countries on 6 continents to define MT access (MTA), the disparities in MTA, and its determinants on a global scale. Methods: Our survey was conducted in 75 countries through the Mission Thrombectomy 2020+ global network between November 22, 2020, and February 28, 2021. The primary end points were the current annual MTA, MT operator availability, and MT center availability. MTA was defined as the estimated proportion of patients with LVO receiving MT in a given region annually. The availability metrics were defined as ([current MT operators×50/current annual number of estimated thrombectomy-eligible LVOs]×100 = MT operator availability) and ([current MT centers×150/current annual number of estimated thrombectomy-eligible LVOs]×100= MT center availability). The metrics used optimal MT volume per operator as 50 and an optimal MT volume per center as 150. Multivariable-adjusted generalized linear models were used to evaluate factors associated with MTA. Results: We received 887 responses from 67 countries. The median global MTA was 2.79% (interquartile range, 0.70–11.74). MTA was <1.0% for 18 (27%) countries and 0 for 7 (10%) countries. There was a 460-fold disparity between the highest and lowest nonzero MTA regions and low-income countries had 88% lower MTA compared with high-income countries. The global MT operator availability was 16.5% of optimal and the MT center availability was 20.8% of optimal. On multivariable regression, country income level (low or lower–middle versus high: odds ratio, 0.08 [95% CI, 0.04–0.12]), MT operator availability (odds ratio, 3.35 [95% CI, 2.07–5.42]), MT center availability (odds ratio, 2.86 [95% CI, 1.84–4.48]), and presence of prehospital acute stroke bypass protocol (odds ratio, 4.00 [95% CI, 1.70–9.42]) were significantly associated with increased odds of MTA. Conclusions: Access to MT on a global level is extremely low, with enormous disparities between countries by income level. The significant determinants of MT access are the country’s per capita gross national income, prehospital LVO triage policy, and MT operator and center availability.
The purinergic receptor P2RX7 promotes the accumulation of effector CD4+ T cells in the lung parenchyma during hypervirulent mycobacterial infection
Carvalho, Igor Santiao, Alves-filho, Jose , Álvarez, José María , Lassounskaia, Elena L, Carvalho, Igor Santiago de, Bomfim, Caio César Barbosa , Santos, Gislane de Almeida , Melo, Bruno Marcel Silva de , Hirata, Mário Hiroyuki , Lassounskaia, Elena, Silva, Henrique Borges da , Lima, Maria Regina D’Império

Mayo Clinic

The Journal of Immunology | February 7, 2023 | Volume: 206 | Issue: 1_Supplement | Pages: 16.26-16.26

10.4049/jimmunol.206.supp.16.26 Get It

Abstract CD4+ T cells are crucial to control pulmonary tuberculosis, but also favor uncontrolled inflammation in severe disease. Effective CD4+ T cell response to tuberculosis is related to tissue location: Lung-resident CD4+ T cells display higher effector function in comparison to circulating cells. Among the factors favoring T cell residency in non-lymphoid tissues, extracellular ATP sensing via P2RX7 is crucial for the generation of virus-specific resident memory CD8+ T cells. Yet, its role in CD4+ T cell non-lymphoid tissue residency has not been defined. Moreover, mycobacterial infection induces high extracellular ATP levels due to lung tissue damage, which is increased in response to hypervirulent strains. Here, we used P2rx7 ablation models to test the role of P2RX7 in CD4+T cell function in tuberculosis. In response to the hypervirulent Mycobacterium bovis MP287/03 strain, lung-resident WT CD4+ T cells express higher P2RX7 levels compared to circulating CD4+ T cells. Compared to WT mice, P2RX7-deficient (P2rx7−/−) mice display reduced numbers of antigen-specific (I-AbESAT-64-17) and IFN-γ-producing CD4+ T cells in the lung parenchyma. Using cell adoptive transfers, while recipient CD4-deficient mice transferred with CD4+ WT T cells are protected, mice that received CD4+P2rx7−/− T cells develop severe tuberculosis. Mechanistically, CD4+P2rx7−/− T cells have poorer accumulation and IFN-γ production in the lung parenchyma; moreover, they show reduced proliferation in situ. This defect in proliferation is exclusively observed in the lung, with no differences observed in draining lymph nodes. Together, our results show that P2RX7 promote the accumulation of protective CD4+ T cells in the lung during severe tuberculosis.
Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort
Vollstedt, Eva‐Juliane , Schaake, Susen , Lohmann, Katja , Lesage, Suzanne , Tesson, Christelle , Wurster, Isabel , Hentati, F., Marder, Karen, Waters, Cheryl , Fahn, Stanley, Brüggemann, Norbert , Tolosa, Eduardo , Garrido, Alícia , Annesi, Grazia , Bozi, Maria , Ferreira, Joaquim J. , Guedes, Leonor Correia , Petrucci, Simona , Clark, Lorraine N. , Abramycheva, Natalya, Menéndez‐González, Manuel , Maestre, S. Jesús, Gómez‐Garre, Pilar , Mir, Pablo , Ran, Caroline , Kuo, Ming‐Che , Ross, Owen A. , Williams‐Gray, Caroline H. , Camacho, Marta , Cornejo‐Olivas, Mario , Torres-Ramírez, Luis , Wu, Yih‐Ru , Morgadinho, Ana , Berg, Daniela , Kuhlenbäumer, Gregor , Kühn, Andrea A. , Borngräber, Friederike , Michele, Giuseppe De , Rosa, Anna De , Zimprich, Alexander , Puschmann, Andreas , Mellick, George D. , Chase, Bruce A. , Markopoulou, Katerina , Satake, Wataru , Rossi, Malco , Lynch, Timothy , Olszewska, Diana A. , Lim, Shen‐Yang , Ahmad‐Annuar, Azlina , Tan, Ai Huey , Hanağası, Haşmet , Koziorowski, Dariusz , Ertan, Sibel , Genç, Gençer , Saunders‐Pullman, Rachel , Warrenburg, Bart van de, Bressman, Susan , Toft, Mathias , Appel‐Cresswell, Silke , Boon, Agnita J.W. , Krüger, Rejko , Sammler, Esther , Tumas, Vítor , Zhang, Baorong , Garraux, Gaëtan , Kim, Yun Joong , Winkelmann, Juliane , Sue, Carolyn M. , Tan, Eng‐King , Kostić, Vladimir , Arkadir, David , Martikainen, Mika H. , Brighina, Laura , Suchowersky, Oksana , Rieß, Olaf , Das, Parimal, Mollenhauer, Brit , Gatto, Emilia , Petersen, Maria Skaalum , Aasly, Jan , Aasly, Anna, Farrer, Matthew J. , Brockmann, Kathrin , Klein, Christine , Group, the MJFF Global Genetic Parkinson's Disease Study, Bardien, Soraya , Barrett, Matthew J. , Januário, Cristina , Sousa, Mário , Soto‐Beasley, Alexandra I. , May, Patrick , Mirelman, Anat , Brüggemann, Norbert , Borsche, Max , Tolosa, Eduardo , Ferreira, Joaquim J , Alvarez, Victoria , Mir, Pablo , Kuo, Ming-Che , Ross, Owen A , Nishioka, Kenya , Williams-Gray, Caroline H , Camacho, Marta , Cornejo-Olivas, Mario , Wu, Yih-Ru , Termsarasab, Pichet , Borngräber, Friederike , Zimprich, Alexander , Gambardella, Stefano , Chase, Bruce , Olszewska, Diana A , Tan, Ai Huey , Barkhuizen, Melinda , Appel-Cresswell, Silke , Skorvanek, Matej , Sammler, Esther M , Zhang, Baorong , Chung, Sun Ju , Puschmann, Andreas , Januário, Cristina , Klein, Christine , Bardien, Soraya , Toft, Mathias , Koziorowski, Dariusz , May, Patrick , Beasley, Alexandra I , Barrett, Matthew J , Sue, Carolyn M , Kühn, Andrea A , Padmanabhan, Shalini , Brice, Alexis , Vidailhet, Marie , Giladi, Nir , Kasten, Meike , Borsche, Max , Foroud, Tatiana , Gagliardi, Monica , Stefanis, Leonidas , Avenali, Micol , Fedotova, E. Yu. , Álvarez, Victoria , Belin, Andrea Carmine , Lin, Chin‐Hsien , Crosiers, David , Wszołek, Zbigniew K. , Jankovic, Joseph J. , Funayama, Manabu , Clarimón, Jordi , Lee‐Chen, Guey‐Jen , Pulkes, Teeratorn , Dorszewska, Jolanta , Carr, Jonathan , Ferese, Rosangela , Toda, Tatsushi , Merello, Marcelo , Al-Mubarak, Bashayer R , Aguiar, Patrícia de Carvalho , Pimentel, Márcia Mattos Gonçalves , Warrenburg, Bart P.C. van de , Lang, Anthony E. , Damásio, Joana , Klivènyi, Péter , Borges, Vanderci , Hertz, Jens Michael , Spitz, Mariana , Hattori, Nobutaka , Wu, Ruey‐Meei , Illarioshkin, Sergey Nikolaevich , Valente, Enza Maria , Alcalay, Roy N. , Thaler, Avner , Corvol, Jean‐Christophe , Group, the MJFF Global Genetic Parkinson's Disease Study

Mayo Clinic

Movement Disorders | January 24, 2023 | Volume: 38 | Issue: 2 | Pages: 286-303

10.1002/mds.29288 | PMID 36692014 Get It

AbstractBackgroundAs gene‐targeted therapies are increasingly being developed for Parkinson's disease (PD), identifying and characterizing carriers of specific genetic pathogenic variants is imperative. Only a small fraction of the estimated number of subjects with monogenic PD worldwide are currently represented in the literature and availability of clinical data and clinical trial‐ready cohorts is limited.ObjectiveThe objectives are to (1) establish an international cohort of affected and unaffected individuals with PD‐linked variants; (2) provide harmonized and quality‐controlled clinical characterization data for each included individual; and (3) further promote collaboration of researchers in the field of monogenic PD.MethodsWe conducted a worldwide, systematic online survey to collect individual‐level data on individuals with PD‐linked variants in SNCA, LRRK2, VPS35, PRKN, PINK1, DJ‐1, as well as selected pathogenic and risk variants in GBA and corresponding demographic, clinical, and genetic data. All registered cases underwent thorough quality checks, and pathogenicity scoring of the variants and genotype–phenotype relationships were analyzed.ResultsWe collected 3888 variant carriers for our analyses, reported by 92 centers (42 countries) worldwide. Of the included individuals, 3185 had a diagnosis of PD (ie, 1306 LRRK2, 115 SNCA, 23 VPS35, 429 PRKN, 75 PINK1, 13 DJ‐1, and 1224 GBA) and 703 were unaffected (ie, 328 LRRK2, 32 SNCA, 3 VPS35, 1 PRKN, 1 PINK1, and 338 GBA). In total, we identified 269 different pathogenic variants; 1322 individuals in our cohort (34%) were indicated as not previously published.ConclusionsWithin the MJFF Global Genetic PD Study Group, we (1) established the largest international cohort of affected and unaffected individuals carrying PD‐linked variants; (2) provide harmonized and quality‐controlled clinical and genetic data for each included individual; (3) promote collaboration in the field of genetic PD with a view toward clinical and genetic stratification of patients for gene‐targeted clinical trials. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Large Cancer Pedigree Involving Multiple Cancer Genes including Likely Digenic MSH2 and MSH6 Lynch Syndrome (LS) and an Instance of Recombinational Rescue from LS
Greer, Stephanie , Wang, Fan , Shin, Gi Won , Lau, Billy T. , Hu, Yajing, Alvarez, Rocio , Hazelett, Dennis J. , Nguyen, Peter , Aguirre, Francesca Paola, Hendifar, Andrew , Balcom, Jessica R. , Leininger, Anna, Fairbank, Beth, Ji, Hanlee P. , Hitchins, Megan P. , Wang, Fan , Alvarez, Rocio , Balcom, Jessica, Hitchins, Megan P , Hazelett, Dennis J , Vogelaar, Ingrid P. , Haraldsdóttir, Sigurdís , Aguirre, Francesca Paola, Guindi, Maha M.

Mayo Clinic

Cancers | December 30, 2022 | Volume: 15 | Issue: 1 | Pages: 228

10.3390/cancers15010228 | PMID 36612224 Get It

Lynch syndrome (LS), caused by heterozygous pathogenic variants affecting one of the mismatch repair (MMR) genes (MSH2, MLH1, MSH6, PMS2), confers moderate to high risks for colorectal, endometrial, and other cancers. We describe a four-generation, 13-branched pedigree in which multiple LS branches carry the MSH2 pathogenic variant c.2006G>T (p.Gly669Val), one branch has this and an additional novel MSH6 variant c.3936_4001+8dup (intronic), and other non-LS branches carry variants within other cancer-relevant genes (NBN, MC1R, PTPRJ). Both MSH2 c.2006G>T and MSH6 c.3936_4001+8dup caused aberrant RNA splicing in carriers, including out-of-frame exon-skipping, providing functional evidence of their pathogenicity. MSH2 and MSH6 are co-located on Chr2p21, but the two variants segregated independently (mapped in trans) within the digenic branch, with carriers of either or both variants. Thus, MSH2 c.2006G>T and MSH6 c.3936_4001+8dup independently confer LS with differing cancer risks among family members in the same branch. Carriers of both variants have near 100% risk of transmitting either one to offspring. Nevertheless, a female carrier of both variants did not transmit either to one son, due to a germline recombination within the intervening region. Genetic diagnosis, risk stratification, and counseling for cancer and inheritance were highly individualized in this family. The finding of multiple cancer-associated variants in this pedigree illustrates a need to consider offering multicancer gene panel testing, as opposed to targeted cascade testing, as additional cancer variants may be uncovered in relatives.
Platelet Rich Plasma and Platelet-Related Products in the Treatment of Radiculopathy—A Systematic Review of the Literature
Kubrova, Eva , Alvarez, Gabriel A Martinez , Her, Yeng F , Pagan‐Rosado, Robert , Qu, Wenchun , D’Souza, Ryan S. , Martinez Alvarez, Gabriel A , D'Souza, Ryan S

Mayo Clinic

Biomedicines | November 7, 2022 | Volume: 10 | Issue: 11 | Pages: 2813

10.3390/biomedicines10112813 | PMID 36359333 Get It

Back pain with radicular symptoms is associated with detrimental physical and emotional functioning and economic burden. Conservative treatments including physical, pharmacologic and injection therapy may not provide clinically significant or long-standing relief. Regenerative medicine research including Platelet rich plasma (PRP), Platelet lysate (PL) or Plasma rich in growth factors (PRGF) continues to develop, however evidence appraisal for treatment of radicular pain remains lacking. Thus, we performed a systematic review to evaluate the effectiveness of epidural steroid injections containing PRP or related products to treat radicular pain. Embase, PubMed/MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), and Google Scholar databases were queried. Twelve studies were included in qualitative analysis, consisting of three randomized controlled trials and nine observational studies. The primary outcome was pain intensity, and secondary outcomes included functional improvement, anatomical changes on advanced imaging, and adverse events. All studies identified improved pain intensity and functional outcomes after epidural injection of PRP, PRGF and/or PL. Similar or longer lasting pain relief was noted in the PRP cohort compared to the cohort receiving epidural steroid injections with effects lasting up to 12–24 months. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) analysis revealed a very-low certainty of evidence due to risk of bias, indirectness, and imprecision.
Recent Antifungal Pipeline Developments against Candida auris: A Systematic Review
Treviño‐Rangel, Rogelio de J. , Montoya, Alexandra M. , Rojas, Olga C. , Elizondo-Zertuche, Mariana , Álvarez‐Villalobos, Neri Alejandro , Montoya, Alexandra M , Rojas, Olga C , Álvarez-Villalobos, Neri A , González, Gloria María

Mayo Clinic

Journal of Fungi | October 30, 2022 | Volume: 8 | Issue: 11 | Pages: 1144

10.3390/jof8111144 | PMID 36354911 Get It

The alarming spread and impact of multidrug-resistant Candida auris infections alongside the limited therapeutic options have prompted the development of new antifungals. These promising agents are currently in different stages of development, offering novel dosing regimens and mechanisms of action. A systematic search in MEDLINE, EMBASE, Web of Science, and Scopus up to 27 June 2022 was conducted to find relevant articles reporting data of in vitro activity and in vivo efficacy of investigational antifungals against C. auris. These included new additions to existing antifungal classes (rezafungin and opelconazole), first-in-class drugs such as ibrexafungerp, manogepix/fosmanogepix, olorofim and tetrazoles (quilseconazole, oteseconazole and VT-1598), as well as other innovative agents like ATI-2307, MGCD290 and VL-2397. From 592 articles retrieved in the primary search, 27 met the eligibility criteria. The most studied agent was manogepix/fosmanogepix (overall MIC90: 0.03 mg/L), followed by ibrexafungerp (overall MIC90: 1 mg/L) and rezafungin (overall MIC mode: 0.25 mg/L), while VT-1598 and ATI-2307 were the least explored drugs against C. auris. All these compounds demonstrated significant improvements in survival and reduction in tissue fungal burden on neutropenic animal models of candidemia due to C. auris. Continual efforts towards the discovery of new treatments against this multidrug-resistant fungus are essential.
Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials
Martin, Ting , Sun, Yilun , Malone, Shawn , Roach, Mack , Dearnaley, David P. , Pisansky, Thomas M. , Feng, Felix Y. , Sandler, Howard M. , Efstathiou, Jason A. , Syndikus, Isabel , Hall, Emma , Tree, Alison , Sydes, Matthew R. , Cruickshank, Claire, Roy, Soumyajit , Bolla, M. , Reijke, Theo de, Nabid, Abdenour , Carrier, Nathalie , Souhami, Luís, Guerrero, A., Álvarez, A. , Segundo, Carmen González‐San , Maldonado, Xavier , Romero, Tahmineh , Steinberg, Michael L. , Valle, Luca , Nickols, Nicholas G. , Shoag, Jonathan E. , Reiter, Robert E. , Jia, Angela Y. , García, Jorge A. , Spratt, Daniel E. , Kishan, Amar U. , Ma, Ting Martin , Dearnaley, David , Hall, Emma C , Tree, Alison C , Bolla, Michel , Maingon, Philippe , Alvarez, Ana , Gonzalez San-Segundo, Carmen , Steinberg, Michael L , Valle, Luca F , Shoag, Jonathan E , Zaorsky, Nicholas G , Spratt, Daniel E , Kishan, Amar U , Sandler, Howard M , Efstathiou, Jason A , Zapatero, A. , Rettig, Matthew B. , Zaorsky, Nicholas G.

Mayo Clinic

Journal of Clinical Oncology | October 21, 2022 | Volume: 41 | Issue: 4 | Pages: 881-892

10.1200/jco.22.00970 | PMID 36269935 Get It

PURPOSE The sequencing of androgen-deprivation therapy (ADT) with radiotherapy (RT) may affect outcomes for prostate cancer in an RT-field size-dependent manner. Herein, we investigate the impact of ADT sequencing for men receiving ADT with prostate-only RT (PORT) or whole-pelvis RT (WPRT). MATERIALS AND METHODS Individual patient data from 12 randomized trials that included patients receiving neoadjuvant/concurrent or concurrent/adjuvant short-term ADT (4-6 months) with RT for localized disease were obtained from the Meta-Analysis of Randomized trials in Cancer of the Prostate consortium. Inverse probability of treatment weighting (IPTW) was performed with propensity scores derived from age, initial prostate-specific antigen, Gleason score, T stage, RT dose, and mid-trial enrollment year. Metastasis-free survival (primary end point) and overall survival (OS) were assessed by IPTW-adjusted Cox regression models, analyzed independently for men receiving PORT versus WPRT. IPTW-adjusted Fine and Gray competing risk models were built to evaluate distant metastasis (DM) and prostate cancer–specific mortality. RESULTS Overall, 7,409 patients were included (6,325 neoadjuvant/concurrent and 1,084 concurrent/adjuvant) with a median follow-up of 10.2 years (interquartile range, 7.2-14.9 years). A significant interaction between ADT sequencing and RT field size was observed for all end points ( P interaction < .02 for all) except OS. With PORT (n = 4,355), compared with neoadjuvant/concurrent ADT, concurrent/adjuvant ADT was associated with improved metastasis-free survival (10-year benefit 8.0%, hazard ratio [HR], 0.65; 95% CI, 0.54 to 0.79; P < .0001), DM (subdistribution HR, 0.52; 95% CI, 0.33 to 0.82; P = .0046), prostate cancer–specific mortality (subdistribution HR, 0.30; 95% CI, 0.16 to 0.54; P < .0001), and OS (HR, 0.69; 95% CI, 0.57 to 0.83; P = .0001). However, in patients receiving WPRT (n = 3,049), no significant difference in any end point was observed in regard to ADT sequencing except for worse DM (HR, 1.57; 95% CI, 1.20 to 2.05; P = .0009) with concurrent/adjuvant ADT. CONCLUSION ADT sequencing exhibits a significant impact on clinical outcomes with a significant interaction with field size. Concurrent/adjuvant ADT should be the standard of care where short-term ADT is indicated in combination with PORT.
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Armstrong, Deborah K. , Barroilhet, Lisa , Chitiyo, Viola C., Cristea, Mihaela , Eisenhauer, Eric , Gray, Heidi J. , Hakam, Ardeshir, Jain, Angela, Karam, Amer , Konecny, Gottfried E. , McHale, Michael , Miller, David S. , Percac‐Lima, Sanja , Remmenga, Steven W., Schorge, John O., Vargas, Roberto , Hendrickson, Andrea Wahner, Werner, Theresa L. , Dwyer, Mary A., Hang, Lisa E., Miller, David S , Alvarez, Ronald D. , Backes, Floor , Bakkum‐Gamez, Jamie N. , Behbakht, Kian , Berchuck, Andrew , Chen, Lee-may , Chitiyo, Viola, DeRosa, Maria, Gershenson, David M. , Grisham, Rachel Nicole , Leath, Charles A , Leiserowitz, Gary S. , Liu, Joyce F. , Martin, Lainie P. , Matei, Daniela , McLean, Karen , Stewart, Daphne B. , Thaker, Premal H. , Zsíros, Emese

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 8, 2022 | Volume: 20 | Issue: 9 | Pages: 972-980

10.6004/jnccn.2022.0047 | PMID 36075393 Get It

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years following diagnosis. The NCCN Guidelines for Ovarian Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with ovarian, fallopian tube, and primary peritoneal cancers. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised guidance on alternative chemotherapy regimens for patients with advanced age and/or comorbidities, a new algorithm for recurrent low-grade serous carcinoma based on developing research and novel therapeutic agents, and updated language regarding tumor molecular analysis applications in ovarian cancer.
Differential Vulnerability of Hippocampal Subfields in Primary Age-Related Tauopathy and Chronic Traumatic Encephalopathy
Farrell, Kurt , Iida, Megan A., Cherry, Jonathan D. , Casella, Alicia, Stein, Thor D. , Bieniek, Kevin F. , Richardson, Timothy E. , Alvarez, Victor E., Huber, Bertrand R. , Insausti, Ricardo , Group, The Part Working, Vonsattel, Jean‐Paul, Teich, Andy F, Gearing, Marla , Glass, Jonathan D. , Troncoso, Juan C. , Frosch, Matthew P. , Attems, Johannes , Mesulam, M-Marsel, Weıntraub, Sandra , Woltjer, Randy, Pham, Thao, Kofler, Julia , Yu, Lei , Purohit, Dushyant P. , Haroutunian, Vahram , Sano, Mary , Beach, Thomas G. , Kawas, Claudia H. , Metcalf, Jeff , Shuldberg, Sara, Salehi, Bahar , Nelson, Peter T. , Trojanowski, John Q. , Latimer, Caitlin S. , Montine, Thomas J. , Kovács, Gábor G. , Lutz, Mirjam I. , Perrin, Richard J. , Cairns, Nigel J. , McKee, Ann C. , Crary, John F. , Kovacs, Gabor G , Farrell, Kurt , Walker, Jamie M. , White, Charles L. , Dickson, Dennis W. , Dams-O’Connor, Kristen , Group, The Part Working, Teich, Andy F, Hyman, Bradley T. , Murray, Melissa E. , Flanagan, Margaret E. , Mao, Qinwen , Schneider, Julie A. , Yu, Lei , Hof, Patrick R. , Gandy, Sam , Poon, Wayne W. , Corrada, María M. , Rissman, Robert A. , Lee, Edward B. , Wolk, David A. , McMillan, Corey T. , Keene, C. Dirk , Fischer, Peter A.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | August 25, 2022 | Volume: 81 | Issue: 10 | Pages: 781-789

10.1093/jnen/nlac066 | PMID 36004533 Get It

Abstract Chronic traumatic encephalopathy (CTE) is a tauopathy associated with repetitive mild head impacts characterized by perivascular hyperphosphorylated tau (p-tau) in neurofibrillary tangles (NFTs) and neurites in the depths of the neocortical sulci. In moderate to advanced CTE, NFTs accumulate in the hippocampus, potentially overlapping neuroanatomically with primary age-related tauopathy (PART), an age-related tauopathy characterized by Alzheimer disease-like tau pathology in the hippocampus devoid of amyloid plaques. We measured p-tau burden using positive-pixel counts on immunohistochemically stained and neuroanatomically segmented hippocampal tissue. Subjects with CTE had a higher total p-tau burden than PART subjects in all sectors (p = 0.005). Within groups, PART had significantly higher total p-tau burden in CA1/subiculum compared to CA3 (p = 0.02) and CA4 (p = 0.01) and total p-tau burden in CA2 trended higher than CA4 (p = 0.06). In CTE, total p-tau burden in CA1/subiculum was significantly higher than in the dentate gyrus; and CA2 also trended higher than dentate gyrus (p = 0.01, p = 0.06). When controlling for p-tau burden across the entire hippocampus, CA3 and CA4 had significantly higher p-tau burden in CTE than PART (p &lt; 0.0001). These data demonstrate differences in hippocampal p-tau burden and regional distribution in CTE compared to PART that might be helpful in differential diagnosis and reveal insights into disease pathogenesis.